Loading

Loading page data

Please wait a moment

UK

Corporate Office

Persistence Research & Consultancy Services Limited

Company Number : 15310893

Second Floor, 150 Fleet Street,London, EC4A 2DQ.

+44 203-837-5656
India

Global Research centre

Persistence Market Research Private Limited

CIN : U74900PN2014PTC153163

IT Unit No. 504, 5th Floor, IconTower, Baner, Pune - 411045.

+91 906 779 3500

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -
Request For Customization Obesity GLP-1 Market by Drug Type (Semaglutide, Tirzepatide, Liraglutide & Generics, Orforglipron, CagriSema, Pipeline Dual Agonists, Next-Gen Triple Agonists), Therapeutic Indication (Primary Weight Management, Obesity + Type 2 Diabetes, Obesity + CVD, Obesity + Sleep Apnea, Obesity + Liver Disease (MASH), Obesity + Heart Failure, Obesity + CKD), Route of Administration (Injectable, Oral), and Regional Analysis for 2026 - 2033